Tharimmune announces initiation of phase 1 clinical trial of th104 and provides business update

Phase 1 trial initiated to assess safety/tolerability and absolute bioavailability of th104 with topline data expected in 2q24 planning well underway for phase 2 of th104 in primary biliary cholangitis (pbc) patients suffering from moderate-to-severe chronic pruritus company outlines near-clinical pipeline of novel antibody technology for multiple immuno-oncology targets and plans an r&d day in 2024 company fully funded into 2025 with full readouts of phase 1 and phase 2 results for moderate-to-severe chronic pruritus in pbc expected in 4q24/1q25 bridgewater, nj / accesswire / january 29, 2024 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology announces initiation of a phase 1 trial with th104, utilizing a proprietary oral thin film. th104 is a proprietary transmucosal buccal film embedded with the active compound nalmefene onto a thin film which easily adheres inside of the mouth on the cheek and biodegrades within minutes.
THAR Ratings Summary
THAR Quant Ranking